Novel antiretroviral formulations that are palatable, safe, and effective are needed for infants and children.
PRINCE-2 is an ongoing clinical trial assessing safety, efficacy, and palatability of once-daily atazanavir powder formulation boosted with ritonavir (ATV+RTV) plus optimized dual NRTI therapy in ARV-naïve/experienced children with screening HIV-1 RNA ≥1000 copies/mL. Children aged 3 months to <11 years received ATV+RTV by 5 baseline weight bands: 5 to <10kg=150/80mg; 5 to <10kg=200/80mg; 10 to <15kg=200/80mg; 15 to <25kg=250/80mg; and 25 to <35kg=300/100mg.
Of 99 treated children, 83.8% and 59.6% remained on ATV powder until 24 and 48 weeks, respectively. Through 48 weeks, the most common adverse events (AEs) were upper respiratory tract infections (33.3%), gastroenteritis (28.3%), vomiting (21.2%), and hyperbilirubinemia (18.2%; none leading to treatment discontinuation). Serious AEs occurred in 20.2% of patients. Laboratory Grade 3–4 hyperbilirubinemia occurred in 9.2% and elevated total/pancreatic amylase in 33.7%/3.1%. At Week 24, proportions with virologic suppression (HIV-1 RNA <50 copies/mL; intention-to-treat analysis) across weight bands were 10/23 (43.5%), 2/12 (16.5%), 10/21 (47.6%), 19/35 (54.3%), and 5/8 (62.5%), respectively. Virologic suppression was similar in antiretroviral-naïve/experienced patients, and lowest in the 5 to <10kg=200/80mg-group, likely due to higher baseline HIV-1 RNA and discontinuation (66.7%). Overall, virologic suppression at Weeks 24 (46.5%) and 48 (43.0%) was comparable. At Week 48, 83.3% and 74.1% of caregivers reported no trouble giving ATV powder and RTV, respectively.
ATV powder palatability, efficacy and lack of unexpected safety findings support its use for HIV-1-infected children aged ≥3 months to <11 years.
Conflicts of Interest and Source of Funding: This study was supported by Bristol-Myers Squibb, the manufacturer of atazanavir. MFC declares funding for his institution from Bristol-Myers Squibb for the conduct of the present study; his institution has received other funding for pharmaceutical trials from ViiV Healthcare, Gilead Sciences, Novovax, VPM-Gmbh, and Novartis; and NIH funding: NIAID through IMPAACT and ACTG trial networks and NIMH.
AL declares no conflicts of interest.
IT-E declares receiving honoraria for speaker engagements for Merck Sharpe & Dohme; Stendhal Pharma, and AbbVie.
MIG-T declares receiving honoraria for speaker engagements for ViiV, Janssen-Cilag and AbbVie; she has also received a Gilead fellowship.
JL, LZ, IK, DC, and TAC are all employees of and own stock in Bristol-Myers Squibb.
CP was an employee of Bristol-Myers Squibb at the time this study was conducted and is now an employee of Gilead Sciences, Inc.
ACKNOWLEDGMENTS: The authors thank Benjamin Dale and Julian Martins of inScience Communications, Springer Healthcare, who provided medical writing support funded by Bristol-Myers Squibb.
Address for Correspondence: Mark F. Cotton, Faculty of Medicine Health Sciences, Stellenbosch University, Ward J8, Tygerberg Academic Hospital, Francie Van Zijl Drive, Parow Valley, PO Box 241, Cape Town 8000, South Africa. Tel: +27 21 938-4219; Fax: +27 21 938-4153; E-mail: email@example.com
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.